TrialsgrambetaRCTs are beautiful

RAPID

2015

Randomized, Placebo-Controlled Trial of A1-PI Augmentation in Severe AATD

In 180 patients with severe (PiZZ) α-1-antitrypsin deficiency and emphysema, intravenous A1-PI augmentation 60 mg/kg weekly slowed annual loss of CT lung density compared with placebo.

Result

Primary endpoint: Annual CT lung-density decline at total lung capacity

-1.45 vs -2.19 g/L/year (difference 0.74; p=0.03); FEV1 changes similar.

Original publication
Subtopic
Augmentation therapy
Design
Multicentre RCT, 24 months
Relevance
Supporting: context rather than must-know.
Source
Chapman KR, et al. Lancet. 2015;386(9991):360-368.doi 10.1016/S0140-6736(15)60860-1

Discussion & critique

First randomised proof that IV augmentation slows emphysema progression on densitometry; FEV1 endpoint remains unproven.